Clinical Trials on Advanced Melanoma

Total 8781 results

Diwakar Davar
Merck Sharp & Dohme LLC; Gateway for Cancer Research

Not yet recruiting

Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma

PD-1 Refractory Advanced Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Metastatic Melanoma | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States
Dana-Farber Cancer Institute
Novartis

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)

Mucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged Melanomas

United States
Multitude Therapeutics Inc.

Recruiting

AMT-253 in Patients With Advanced Solid Tumours

Advanced Solid Tumors | Malignant Melanoma

China
Fudan University

Not yet recruiting

PD-1 Inhibitors With or Without Radiation in Advanced Melanoma

the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma

China
Fox Chase Cancer Center
Incuron

Suspended

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Locally Advanced or Metastatic Melanoma

United States
Institut Català d'Oncologia

Completed

Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma

Locally Advanced or Metastatic Melanoma

Spain
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

United States, Sweden, Australia, France, Italy, South Africa, Spain, United Kingdom, Germany, Netherlands, Israel, New Zealand, Belgium, Switzerland
Thomas Jefferson University

Not yet recruiting

Neoadjuvant Tebentafusp for Uveal Melanoma

Locally Advanced Unresectable Uveal Melanoma

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial (ACTIVATE)

Advanced Ovarian Cancer | Malignant Melanoma

Canada
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Completed

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Melanoma | Malignant Melanoma | Melanoma, Experimental | Experimental Melanomas

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; Array BioPharma

Recruiting

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditions

United States
University of California, Los Angeles
University of California, San Francisco; University of California, Irvine

Active, not recruiting

UC Health Care Planning Study

Advanced Cancer | Advance Care Planning | Advance Directives

United States
Fachklinik Hornheide an der Universität Münster

Unknown

Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases

Advanced Metastastic Malignant Melanoma | Refractory to First-Line Chemotherapy Irresectable Progressive Soft Tissue Metastases

Germany
National Cancer Institute (NCI)

Active, not recruiting

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
MelanomaPRO, Russia

Recruiting

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice (ISABELLA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, Ocular

Russian Federation
Viewpoint Molecular Targeting
Mayo Clinic

Completed

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (TIMAR1)

Melanoma (Skin) | Melanoma Stage IV | Melanoma, Uveal | Melanoma, Mucosal

United States
Delcath Systems Inc.

Active, not recruiting

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
Shanghai Juncell Therapeutics
Shanghai 10th People's Hospital

Recruiting

Study on TIL for the Treatment of Advanced Melanoma

Treatment Side Effects | Effects of Immunotherapy | Advanced Melanoma | Tumor Infiltrating Lymphocyte

China
Scancell Ltd

Recruiting

SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)

Melanoma (Skin) | Malignant Melanoma | Melanoma Stage IV | Melanoma Stage III

United Kingdom
National Cancer Institute (NCI)

Terminated

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
Dana-Farber Cancer Institute
Partner Therapeutics (PTx)

Withdrawn

Sargramostim (GM-CSF) + PD-1

Metastatic Melanoma | Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Hoffmann-La Roche

Completed

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma

Spain, United States, Belgium, Denmark, Canada, Australia
University of California, Irvine
Pfizer

Completed

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Melanoma | Malignant Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA Melanoma

United States
Aura Biosciences

Completed

Study in Subjects With Small Primary Choroidal Melanoma

Ocular Melanoma | Uveal Melanoma | Choroidal Melanoma

United States
University of California, Irvine
GlaxoSmithKline

Completed

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Yale University
National Cancer Institute (NCI)

Completed

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

FDG-PET in Advanced Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Genzyme, a Sanofi Company

Withdrawn

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Stage IIB Melanoma | Stage IIC Melanoma | Stage IB Melanoma | Stage IIA Melanoma

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Oxford University Hospitals NHS Trust
University of Oxford; Barts & The London NHS Trust; Ninewells Hospital

Completed

Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors (EUNASS)

Melanoma Stage III | Melanoma, Stage II | Melanoma, Stage I

United Kingdom
National Cancer Institute (NCI)

Terminated

Dinaciclib in Treating Patients With Stage III-IV Melanoma

Stage IV Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Terminated

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Aura Biosciences

Active, not recruiting

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Ocular Melanoma | Uveal Melanoma | Choroidal Melanoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Dana-Farber Cancer Institute
AstraZeneca

Withdrawn

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Recurrent Metastatic Melanoma

United States
Craig L Slingluff, Jr
University of Virginia

Completed

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (MEL60)

Melanoma | Metastatic Melanoma | Mucosal Melanoma

United States
Craig L Slingluff, Jr
Celldex Therapeutics

Active, not recruiting

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (Mel66)

Melanoma | Ocular Melanoma | Uveal Melanoma

United States
Ludwig Institute for Cancer Research
University of Chicago; University of Pittsburgh; Life Science Pharmaceuticals

Completed

Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

Metastatic Melanoma | Cutaneous Melanoma

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069)

Metastatic Melanoma | Unresectable Melanoma

United States, France
Fondazione Melanoma Onlus
Roche S.p.a

Terminated

Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients (VECODUE)

Melanoma | Melanoma (Skin) | Melanoma Stage

Italy
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC Melanoma

United States

Clinical Trials on Advanced Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations